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Nanoparticles have attracted the interest of many research groups and had been utilized in an increasing 
number of fields during the last decades. Various methods can be used to produce   nanoparticles such as solvent 
evaporation, salting-out, dialysis, supercritical fluid technology, micro-emulsion, emulsion cross linking and 
interfacial polymerization. This review covers the general description, preparation and the detailed description of 
the crucial parameters involved in techniques designed to obtain the desired properties of nanoparticles. 
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Nanoparticles (NP) are a type of colloidal drug delivery system comprising particles with 
a size range from 10 to 1000nm in diameter and are used to deliver the drugs or biomolecules. 
The word ‘nano’ is derived from Latin word, which means dwarf. Nano size refers to one 
thousand millionth of a particular unit thus nanometer is one thousand millionth of a metre (i.e. 
1nm = 10-9
 m)[30]. Generally, nanometric carriers also comprise sub-micron particles with size 
below 1000 nm. They are drug carriers of natural, semisynthetic, and synthetic polymeric 
nature in the nanometer size range. Nanoparticles may or may not be are a collective name for 
nanospheres and nanocapsules as illustrated in Fig. 1. Nanospheres possess a matrix type 
structure, where drugs or biomolecules are absorbed or dissolved or entrapped within the 
polymeric carrier. Nanocapsules are vesicular system in which the drug or bioactive molecule 
forms a core, which is surrounded by a polymeric membrane. In this case the active substances 
are usually dissolved in the inner core but may also be absorbed at their surface [59]. 
Conventional preparations like solution, suspension or emulsion suffer from certain limitations 
like higher dose requirements due to low bioavailability, often associated with first pass effect, 
intolerance and instability. Moreover, they are associated with fluctuations in plasma drug 
levels and do not provide sustained effect. Therefore, some novel carriers are need of the hour, 
which could meet ideal requirement of drug delivery system. Nanoparticles may or may not be 
associated with other nanosize-related properties that differ significantly from those observed 
in fine particles or bulk materials. 
 
 




The ideal requirements for designing nanoparticulate delivery system are to effectively 
control particle size, surface properties, enhance solubility and release of pharmacologically 
active ingredients in order to achieve the site-specific delivery at predetermined rate. Although, 
liposomes have also been used as potential carriers with unique advantages including 
biocompatibility, targeting to site of action and reduction in toxicity or side effects, their 
applications are limited due to inherent problems like low encapsulation efficiency, rapid 
leakage of drug and poor storage stability. On the other hand, polymeric nanoparticles offer 
some specific advantages over liposomes. Polymeric nanoparticles offer stability of 
drugs/proteins and possess useful controlled release properties. 
 
Various methods had been utized for preparing nanoparticles depending on the 
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physicochemical properties of the polymer and the drug. Most of the methods involve the use 
of organic solvents, heat, sonication or vigorous agitation which may affect the stability of 
active pharmaceutical ingredients. Nanoparticles can also be formulated by utilizing 
electrostatic interaction between charged species. These polyelectrolyte complexes can be 
formulated by avoiding such stresses asoociated with other methods of preparation, therefore 
minimizing possible damage to drug during formulation. A variety of biodegradable polymers 
with diverse physicochemical properties are available to formulate nanoparticles. These 
polymers are either natural or synthetic. Natural polymeric carriers used for oraly delivered 
nanoparticles include chitosan, dextran, gelatine, alginate, agar among which chitosan is the 
most popular one. 
 
Chitosan is biocompatible, non-toxic and mucoadhesive derivative obtained from 
natural source. It is a widely available modified natural carbohydrate polymer prepared by the 
partial N-deacetylation of chitin obtained from shells of crustaceans like crabs, prawns etc. The 
physicochemical properties of chitosan are significantly influenced by its molecular weight and 
degree of deacetylation. The presence of reactive functional groups in chitosan provides great 
opportunity for chemical modification, which allows formulation of a wide range of derivatives 
possessing unique properties. Chitosan is soluble at lower pH although it has limited solubility 
at pH above 6.5. Derivatives of chitosan, synthesized by introducing alkyl groups to amine 
groups, e.g. quaternized derivatives of chitosan, are permanently positively charged and posess 
better aqueous solubility. Chitosan is able to increase intestinal permeability by opening tight 
junctions. Chitosan can form polyelectrolyte complexes of approximately 200 to 400 nm. 
Overall, it is evident that Chitosan and its derivatives are useful carriers, owing to their 
biocompatible and biodegradable nature inaddition to other physicochemical properties. 
Currently, dietary supplements of chitosan are tested in clinical trials to lower blood cholesterol 
but no clinical trials with chitosan nanoparticles are ongoing. Other polysachharides like 
dextran, gelatine and alginate are also being investigated for medical applications due to their 
biocompatibility [53]. 
 
Advantages of Nanoparticles 
 
 Improved stability i.e. long shelf life.   
 Increased solubility of the drug.  
 High carrier capacity or high drug entrapment efficiency. 
 The drug can be incorporated without any chemical reaction, which is a prerequisite for 
preserving the drug activity.(Wu et al.,2011) 
 Particle size and surface characteristics of nanoparticles can be easily manipulated to 
achieve both passive and active drug targeting.                                     
 Targeted and controlled drug delivery is possible  
 Increased therapeutic efficacy and reduction in side effects.(Gelperina et al.,2005) 
 Drug and particle degradation characteristics can be easily modulated by proper 
selection of matrix constituents. 
 Drug loading is relatively high  
 Site-specific targeting can be achieved by attaching targeting ligands to surface of 
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particles or use of magnetic guidance. 
 Nanoparticles can be used for various routes of administration including oral, nasal, 
parenterals, intra-ocular etc. 
 They can be tailor-made to achieve both controlled drug release and disease specific 
localization by controlling the polymer characteristics and surface chemistry. 
 Due to smaller size they are better suited for intravenous (i.v.) delivery without resulting 
in embolism. 
 Nanoparticles are effective in sustaining the drugs thus allowing a more efficient 
interaction with the receptors which are cytoplasmic [22]. 
 Decrease the toxic side effects of the drug. 
 Allow rapid formulation development. 
 Scale up to large scale production is feasible. 
 
Limitations of Nanoparticles 
 
 Their small size and large surface area can lead to particle-particle aggregation. 
 Making physical handling of nanoparticles difficult in liquid and dry forms. 
 Small particles size and large surface area may result in limited drug loading and burst 
release. 
 




Polymeric nanoparticles (PNPs) are prepared from a synthetic or semisynthetic 
polymeric block to increase the circulation half-life and to reduce phagocytic uptake and 
inactivation of the therapeutic moiety and can be used to deliver and target therapeutic agents. 
They are formulated by incorporating biodegradable polymers inorder to maximize tissue 
compatibility and minimize cytotoxicity. A number of polymers  are approved by the U.S. Food 
and Drug Administration (FDA) for administration in human beings viz. polylactic acid (PLA), 
poly(glycolic acid) (PGA), PLGA, poly-ecaprolactone, and poly(methyl methacrylate).  PLA and 
PLGA can easily be hydrolyzed into individual monomers (lactic acid or glycolic acid), which are 
removed from the body via normal metabolic pathways. Methods of preparation of PNPs may 
be categorized two major classes: one deals with the polymerization of monomers (eg, 
emulsion and dispersion polymerization), whereas the other essentially involves dispersion of 
polymers (eg, salting out, emulsification- diffusion, and nanoprecipitation). It had been 
reported that higher entrapment efficiency in PNPs can be achieved by incorporation of drug 
during their preparation rather than adsorption on preformed nanoparticles.(Wong et al.,2010) 
Drug release takes place in polymeric nanoparticles through their simultaneous biodegradation, 
followed by desorption, diffusion, or erosion.  
 
Solid Lipid Nanoparticles 
 
Solid lipid nanoparticles (SLNs) are a comparatively stable colloidal carrier system in 
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which molten lipid is dispersed in an aqueous media containing surfactant by high-pressure 
homogenization or microemulsification [8]. They are generally made up of a solid hydrophobic 
core containing the drug dissolved or dispersed. SLNs exhibit certain potential advantages over 
PNPs. They can have better brain uptake and exhibit the least toxicity due to the biodegradable 
nature of the carrier lipid. Smaller size (around 10 to 200 nm) and narrow size range (100 to 200 
nm) allows them to cross tight endothelial cells of the blood brain barrier (BBB), escape from 
the reticuloendothelial system (RES), and bypass the liver [47]. They have comparatively higher 
drug entrapment efficiency, render the drug more stable in their lipid matrix and provide 
sustained release of drug lasting up to several weeks. Their production can be scaled up with 
excellent reproducibility and therefore they can be easily transferred from labs to actual large 




Magnetically targeted nanoparticulate drug delivery systems involve binding of drug 
with magnetic nanoparticles (MNPs), such as oxidized iron (Fe) or magnetite. By virtue of their 
controllable sizes (ranging from 10 to 100 nm) and capacity of delivering the drug or 
biomolecules in the vicinity of a target site, they hold a lot of potential for targetted drug 
delivery especially in treatment of cancer as well as in diagnostics. For biomedical applications, 
magnetic carriers must be water based, biocompatible, nontoxic, and nonimmunogenic. 
Various magnetic carriers, which receive external magnetic field, include nickel, cobalt, iron, 
and magnetite. Iron oxide is most commonly used due to its biodegradable nature, 
biocompatibility, super paramagnetic effects, and capacity to serve as a contrast agent in 
magnetic resonance imaging (MRI). Iron oxide particles are phagocytosed or endocytosed by 
the Kupffer cell in the RES of liver, spleen, lymph, and bone marrow. Once compartmentalized 
within the lysosomes of RES cells, they are broken down into ferritin and/or hemosiderin, which 
are antiferromagnetic forms of iron. The concentration of carriers at any specific location can 
be manipulated by calculation of capillary flow rate, vascular permeability, and hydrodynamic 
condition prevalent at the target site as well as pathophysiology of the individual. For 
therapeutic effect, MNPs are injected into the bloodstream and a high gradient magnetic field 
is generated outside the body so as to pull them out of biological stream and deliver the drug to 
a localized disease site[69]. 
 
Metal and Inorganic Nanoparticles 
 
Nanoparticles have also been prepared using various metals, such as gold (Au), copper 
(Cu), and silver (Ag) and inorganic carriers, like silica or alumina, among which gold 
nanoparticles are widely being invesigated due to their excellent optical and photoelectric 
properties. Moreover, gold nanoparticles exhibits some specific advantages, like inertness and 
nontoxicity, higher  stability, ease of preparation, and possibility of bioconjugation and 
biomodification with thiol, disulfide, and amine functional groups. Its dispersion stability can be 
enhanced by conjugation with thiolated PEG. Gold nanoparticles are highly effective contrast 
agents in cancer diagnosis and photodermal cancer therapy. Furthermore, they serve as a good 
vector for oligonucleotide, thiol-conjugated small interfering RNA (Si-RNA), insulin, and gene 
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Quantum dots (QDs) are colloidal semiconductor nanocrystals (up to 2 to 10 nm), 
composed of atoms from groups II–VI or III–V of the periodic table, having unique optical and 
fluorescent properties (Fig. 2). The most commonly used materials for preparation of quantum 
dots are cadmium selenide (CdSe), cadmium telluride (CdTe), and indium arsenide (InAs). Upon 
their interaction with photon, they get excited and emit energy in UV, visible, or near-infrared 
(IR) regions, which can be detected. Owing to their small size, they can be used for the tagging 
of biological macromolecules, such as nucleoside and proteins [48]. 
 




Polymeric micelles (PMs) are nanosized core-shell structures formed by spontaneous 
self-assembly of individual amphiphilic di/tri-block co-polymers with hydrophobic core and 
hydrophilic surface shells or vice versa (Fig.3). They contain both hydrophilic and hydrophobic 
regions in their structure and serve as good carrier systems for poorly soluble drugs. 
Multifunctional polymeric micelles can be also being designed to facilitate simultaneous drug 
delivery and imaging. Their stability depends on strong cohesive force between drug and core 
polymer segments as well as cross-linking of the shell or core, which is performed by radical 
polymerization. Prolonged circulation and targeted delivery of PMs is possible by designing of 
environment-responsive polymeric micelles (pH, light, temperature, ultrasound, etc.). 
                                      
 
Fig.3 Schematic representation of a self-assembled block copolymeric micelle [48] 
 
Sterically Stabilized Micelles 
 
Sterically stabilized micelles (SSMs), containing polyethylene glycol (PEGylated) and 
phospholipids (Phospholipid Micelles), have also been prepared as a safe, biocompatible 
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nanocarriers for the delivery of poorly water-soluble as well as cytotoxic drugs like anticancer 
drugs. Camptothecin-containing SSMs (CPT-SSMs) has been prepared as a novel nanomedicine 
for parenteral administration, which showed higher solubilization potential, estimable stability, 




Liposomes are small artificial vesicles of globular shape composed of aqueous pores 
encapsulated with amphiphilic phospholipids and cholesterol bilayer (Fig. 4) [62]. They are 
widely used owing to their ability to act as carrier for  both hydrophilic as well as hydrophobic 
drugs, and better tissue biocompatibility along with the fact that their size can be suitably 
monitored [37]. Depending on size and number of phospholipid bilayers, liposomes had been 
classified into small unilamellar vesicles (SUVs; single lipid layer 25 to 50 nm in diameter), large 
unilamellar vesicles (LUVs; heterogeneous group of vesicles), and multilamellar vesicles (MLVs; 
several lipid layers separated from one another by a layer of aqueous solution). Liposomes have 
been widely investigated for the delivery of vaccine, toxoids, gene, anticancer, and anti-HIV 
drugs. 
 
Fig. 4 Schematic representation of sterically stabilized liposomes. [48] 
 
Hydrogel nanoparticles (Nanogels) 
 
Hydrogel nanoparticles (NPs) (recently referred to as nanogels) as a family of nanoscale 
particulate materials, have recently attracted a lot of attention of scientists dealing with 
development of newer drug delivery systems. Interestingly, hydrogel nanoparticulate materials 
would demonstrate the features and characteristics of both hydrogels and NPs simultaneously. 
Therefore, it seems that the pharmacy world will benefit from both the hydrophilicity, 
flexibility, versatility, high water absorptivity, and biocompatibility of these particles and all the 
advantages of the NPs, mainly long life span in circulation and the possibility of being actively or 
passively targeted to the desired biophase, e.g. tumor sites. Different methods have been 
adopted to prepare NPs of hydrogel consistency. Besides the commonly used synthetic 
polymers, active research is now focused on the preparation of NPs using naturally occurring 
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Methods of Preparation of Nanoparticles 
 
Nanoparticles can be prepared using a wide variety of materials such as proteins, 
polysaccharides and synthetic and semisynthetic polymers as well as natural gums and 
hydrocolloids. The selection of ideal matrix forming material/ polymeric carrier is made after 
careful consideration of many factors such as: 
  
 Size of nanoparticles required 
 Inherent properties of the drug, e.g., pKa, aqueous solubility and stability  
 Surface characteristics such as charge and permeability  
 Degree of biodegradability, biocompatibility and toxicity  
 Drug release profile desired 
 Antigenicity of the final product. 




This method utilizes the reactive functional amine group of CS to cross-link with 
aldehyde groups of the cross-linking agent. In this method, water-in-oil (w/o) emulsion is 
prepared by emulsifying the CS aqueous solution in the oil phase. Aqueous droplets are 
stabilized with the help of suitable surfactant (Low HLB value). The stable emulsion is cross-
linked by using an appropriate cross-linking agent such as glutaraldehyde, which results into 
hardening of the droplets. The resulting nanoparticles are seperated by centrifugation, filtered 
and washed repeatedly with n-hexane followed by alcohol and then dried. By this method, size 
of the particles can be controlled by controlling the size of aqueous droplets. However, the 
particle size of final product depends upon the extent of cross-linking agent used while 
hardening, in addition to nature and concentration of surfactant along with speed of stirring 
during the formation of emulsion. This method is schematically represented in Fig.5. The 
emulsion cross-linking method has few drawbacks since it involves tedious procedures as well 
as use of harsh cross-linking agents, which might possibly induce chemical reactions with the 
active agent. Moreover, complete removal of the un-reacted crosslinking agent may be difficult 
in this process. 
 
Fig. 5: Schematic representation of preparation of chitosan nanoparticulate systems by emulsion cross-linking 
method. [68] 
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Solvent evaporation method 
 
In this method, the polymer is dissolved in an organic solvent such as dichloromethane, 
chloroform or ethyl acetate, which is also used as the solvent for dissolving the hydrophobic 
drug. The mixture of polymer and drug solution is then emulsified in an aqueous solution 
containing a surfactant or emulsifying agent to form an oil in water (o/w) emulsion.( Fig.6) After 
the formation of stable emulsion, the organic solvent is evaporated either by reducing the 
pressure or by continuous stirring. Particle size was found to be influenced by the type and 
concentrations of stabilizer, homogenizer speed and polymer concentration. In order to 
produce small particle size, often a high-speed homogenization or ultrasonication along with 
suitable surfactant and stabilizer may be employed [78]. 
 
Fig.6 Schematic representation of the emulsification-evaporation technique.  
 
Spontaneous Emulsification or Solvent Diffusion Method 
 
Spontaneous emulsification or Solvent diffusion method is a modified version of solvent 
evaporation method. In this method, the oil phase consists of a water miscible solvent along 
with a small amount of the water immiscible organic solvent and due to the spontaneous 
diffusion of solvents an interfacial turbulence is created between the two phases leading to the 
formation of small particles. As the concentration of water miscible solvent increases, a 
decrease in the size of particle can be achieved. Both hydrophobic and hydrophilic drugs can be 
formulated into nanoparticles by solvent evaporation and solvent diffusion methods. In the 
case of hydrophilic drug, usually a multiple w/o/w emulsion is formulated with the drug 
dissolved in the internal aqueous phase [23]. 
 
Emulsification/solvent diffusion (ESD) is based on the use of organic solvents, and then 
it was suitably modified in accordance with the salting-out technique. The polymeric carrier is 
dissolved in a water miscible solvent such as propylene carbonate and then is saturated with 
water to ensure the initial thermodynamic equilibrium between both the liquids. In order to 
induce the precipitation of the polymer and the consequent formation of nanoparticles, it is 
necessary to facilitate the diffusion of the solvent of the dispersed phase by dilution with an 
excess of water, when the organic solvent is partly miscible with water or with another organic 
solvent in the case where organic solvent is immiscible with water. Subsequently, the polymer-
water saturated solvent phase is emulsified in an aqueous solution containing stabilizer, leading 
to solvent diffusion to the external phase and the formation of nanospheres or nanocapsules, 
depending on the oil-to-polymer ratio. Finally, the solvent is removed by evaporation or 
filtration, depending on its boiling point. This technique offers several advantages, such as high 
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encapsulation efficiencies (generally more than 70%), no requirement of homogenizers, high 
batch-to-batch reproducibility, easier scale-up, simplicity, and capability to yield narrow size 
distribution. Although there are certain limitations/ drawbacks as higher volume of water is to 
be eliminated from the suspension and the leakage of water-soluble drug into the saturated-
aqueous external phase during emulsification, which may lower the encapsulation efficiency. As 




Fig. 7 Schematic illustration of the ESD technique [59] 
 
Polymerization Method     
 
In polymerization methods, monomers are polymerized with sugseqent entrapment of 
drug particles to form nanoparticles or adsorbed on their surface. Drug is incorporated either 
by dissolving in the polymerization medium or by adsorption onto the nanoparticles after 
completion of polymerization [61]. The nanoparticle suspension is then purified to remove 
traces of free stabilizers and surfactants employed for polymerization by ultracentrifugation 
and re-suspending the particles in an isotonic surfactant-free medium.(Fig.8) This technique has 
widely been utilized for formulating polybutylcyanoacrylate or poly(alkylcyanoacrylate) 
nanoparticles. 
 
Fig.8 Schematic representation of polymerization method for the production of nanoparticles 
 
Coacervation or Ionic Gelation Method 
 
The use of ionic interaction between oppositely charged macromolecules to prepare CS 
nanoparticles has attracted much attention because the simplicity of process avoiding other 
stress conditions. In addition, reversible physical cross-linking by electrostatic interaction, 
instead of chemical cross-linking, has been applied to avoid the possible toxicity of reagents and 
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other undesirable effects. Tripolyphosphate (TPP) is a polyanion, which can interact with the 
cationic CS by electrostatic forces. The preparations of TPP–CS complex by dropping CS droplets 
into a TPP solution have been explored for its potential pharmaceutical usage. In the ionic 
gelation method, CS is dissolved in aqueous acetic acid solution to obtain the cation of CS 
(Fig.9), which is then added dropwise under constant stirring to polyanionic TPP solution. Due 
to the complexation between oppositely charged species, CS undergoes ionic gelation and 
precipitates to form spherical particles.  However, TPP/CS microparticles formed have poor 
mechanical strength thus, limiting their usage in drug delivery [51]. 
 
Fig.9. Schematic representation of the emulsification–internal gelation technique using alginate. [59] 
 
Complex Coacervation Methods 
 
Complex coacervation is a spontaneous phase separation process involving two liquid 
phases in colloidal systems, which results by the interaction of two oppositely charged 
polyelectrolytes upon mixing in an aqueous solution. The process leads to formation of 
micrometric or nanometric colloidal particles, depending on substrates or process variables, 
such as pH, temperature, molecular weight, ionic strength, polyelectrolyte concentration, and 
so forth The major drawbacks of this method is poor drug stability and lower drug loading 
efficiency, which, however, can be overcome by cross-linking of the complex by chemical 








Co-precipitation is a modified complex coacervation method for the preparation of 
nanosized core-shell particles having good dispersion stability of hydrophobic (poorly water-
soluble) drugs. Drug loaded nanoparticles are stabilized by diethyl amino ethylcellulose (DEAE)-
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dextran (Ddex as water-soluble, positively charged resin). Ddex is used as a coating layer to 
coprecipitate with negatively charged drug. The method involved precipitation of drug in a 
supersaturated solution, followed by deposition of Ddex onto the precipitated drug particles 
through electrostatic interactions. Transmission electron microscopy (TEM), atomic force 
microscopy (AFM), and zeta potential studies showed typical core-shell nanoparticles, with high 




Spray-drying is a well-known technique to produce powders, granules or agglomerates 
from the mixture of drug and excipient solutions as well as suspensions. The method is based 
on drying of atomized droplets in a stream of hot air and can be applied for formulation of 
nanoparticles [54]. In this method, CS is first dissolved in aqueous acetic acid solution, drug is 
then dissolved or dispersed in the solution along with a suitable cross-linking agent. This 
solution or dispersion is then atomized in a stream of hot air [78]. Atomization leads to the 
formation of small droplets, from which solvent evaporates instantaneously leading to the 
formation of free flowing particles as depicted in Fig.11.Various process parameters are 
required to be carefully controlled in order to get the desired size of particles. Particle size 
depends upon the size of nozzle, spray flow rate, atomization pressure, inlet air temperature 
and extent of cross linking [19]. 
               
 




The salting-out method is widely used in the pharmaceutical industry owing to its high 
yield, purity, speed and simplicity of the operation. The method does not demand thermal 
treatment at any stage of sample processing and therefore, may be especially useful for the 
incorporation of thermolabile drugs. It is based on the phenomenon in which solubility of a 
non-electrolyte in water is decreased upon addition of an electrolyte. This method involves an 
emulsification step avoiding the use of surfactants and chlorinated solvents, where a water-
soluble stabilizing polymer is added to a saturated solution of electrolyte (e.g, sodium chloride, 
magnesium acetate, or magnesium chloride) to obtain a viscous gel. Subsequently, polymer and 
drug are dissolved separately in an organic solvent. Most often, acetone is used as solvent 
because of its solubilizing properties and easier separation from aqueous solution upon salting-
out with electrolytes. Addition of viscous gel into organic phase under continuous stirring 
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causes salting out of the organic solvent, inducing formation of nanoparticles in organic-
aqueous medium (Fig. 12). Finally, both solvent and electrolyte are eliminated by cross-flow 
filtration [50].  
 
 
Fig 12 Schematic of the salting-out technique [59] 
 
 Nanoprecipitation Method 
 
Nanoprecipitation, also known as solvent displacement method, is based on interfacial 
deposition of a polymer after displacement of a semi polar solvent miscible with water from a 
lipophilic solution. Rapid diffusion of the solvent into aqueous phase results in a decrease in the 
interfacial tension between the two phases, which increases the surface area and leads to 
formation of small droplets of organic solvent even without any mechanical stirring. However, it 
provides poor entrapment efficiency for water-soluble drugs [23]. 
 
Supercritical Fluid Methods 
 
Submicrometer-sized and nano-sized particles can also be prepared by using 
supercritical fluid (SCF) technology. A supercritical fluid can either be a liquid or gas and used 
above its thermodynamic critical point of temperature and pressure. Most commonly used SCFs 
are carbon dioxide (CO2) and water [13].  
 
Rapid Expansion of Supercritical Solutions 
 
Rapid expansion of supercritical solutions (RESS) is a useful technique for thermolabile 
drugs and is able to produce finely divided particles of nanometer size range with a precisely 
controlled size distribution (Fig13). The process involves saturation of SCF with the drug and 
depressurization of the obtained solution through a heated nozzle into a low-pressure chamber 
to cause rapid nucleation of the drug yielding more uniform particle size. As the solution is 
allowed to expand across a calibrated orifice, the density decreases gradually and the solute is 
precipitated as finely divided solid fibers or crystals. Expansion at high pressure keeps the 
density high and reduces the flow velocity of particles, thus providing the particles enough 
growth time for clustering and aggregation. Consequently, larger particles are produced at high 
expansion pressure, whereas, expansion into low pressure causes density to become low with 
higher velocity, so that both the flow time and density are less favorable for the growth of 
larger clusters.  
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Fig.13 Rapid expansion supercritical solution method [48] 
 
Supercritical Antisolvent Precipitation 
 
Supercritical antisolvent precipitation (SAS) is now widely being investigated as an 
alternative to the liquid antisolvent precipitation (LAS) for producing micronized particles of 
some antibiotics.(Huerates et al.,2010) In the case of liquid antisolvent processing, removal of 
solvent is a cumbersome process, whereas SAS allows removal of the solvent under reduced 
pressure and results in appearance of sub micrometer-sized particles with narrow size 
distribution.(Amidi et al.,2010) Selection of proper solvent is a prerequisite as SAS technique is 
based on the use of two completely miscible liquid solvents; the drug or solute to be micronized 
should be soluble in the first solvent but not in the second one.(Nagarwal et al.,2009) 
Antisolvent addition can be carried out from the top or bottom of the precipitating 
chamber.(Rao et al.,2004) A faster diffusion of the solvent results in super saturation resulting 
in precipitation of particles in microsized form. Supercritical CO2 is allowed to flow through the 
chamber until the end of precipitation in order to remove the remaining liquid solvent (Fig14). 
Otherwise, the remaining liquid solvent may resolubilize the solutes during depressurization 
step affecting the product quality and stability [16]. 
 
 
Fig.14 Supercritical antisolvent precipitation method 
 
Osmosis Based Method 
 
A novel osmosis based method had recently been proposed (Fig. 15) for the preparation 
of various natural- and synthetic Polymeric Nanoparticles. This method is based on the use of a 
physical barrier, particularly dialysis membrane or common semi-permeable membrane (SPM)  
that allow the passive transport of solvents in order to reduce the mixing of the polymer 
solution with a non solvent.  
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Fig.15 Schematic representation of osmosis based method for preparation of polymer nanoparticles [58] 
 
Polymers used in Preparation of Nanoparticles 
 
The polymers used in the preparation of polymeric nanoparticles can be divided into 
two broad categories.  
 
Biodegradable   Polymers 
 
 Albumin  
 Gelatin   
 Alginic acid/alginates   
 Chitosan  and chitin derivatives 
 Polylactic acid (PLA)   
 Polyglycolic acid (PGA)   
 Polylactide-co-glycolide (PLGA)   
 Poly-e-caprolactone (PCL)   
 Polylactide-co-caprolactone (PLC)   
 Polyalkyl cyanoacrylates [31] 
 
Non-biodegradable  Polymers 
 
 Polymethyl vinyl ether/maleic anhydride   
 Gantrez   
 Polymethyl methacrylates (Eudragit)   
 Polyamidoamines. (PAMAM)  [9, 17, 38] 
 
EVALUATION OF NANOPARTICLES 
 
It is very important to characterize the freeze-dried product and to investigate the 




Structural characterization plays an important role in determining various attributes of a 
          ISSN: 0975-8585 
 
July – September      2012           RJPBCS              Volume 3 Issue 3   Page No. 1201 
 
nanoparticulate system like shape, size, surface morphology, spatial distribution, density, 
geometric feature etc. Scanning electron microscopy (SEM) produces the image down to length 
scales of 10 nm and provides valuable information regarding surface topology, structural 
arrangement, spatial distribution as well as surface morphology of nanoparticles. Transmission 
electron microscopy (TEM) and high resolution TEM are more powerful imaging tools than SEM 
and give more detailed geometrical features and information like crystal structure, quality, and 
orientation of nanoparticles along with varying density of the phases involved. Moreover, 
scanning tunneling probe such as scanning tunneling microscope (STM), electrical field gradient 
microscopy (EFM), and scanning thermal microscopy, combined with atomic force 
microscopy(AFM) are alsonow being employed to illustrate structural, electronic, magnetic and 
thermal properties besides topographical properties of nanosystems [72]. 
 
Particle Size Distribution  
 
Particle size distribution and polydispersity index are one of the most important aspect 
of formulation of nanosystems, efforts are always made to achieve a system with narrow 
particle size distribution with lowest polydispersity index. Some techniques to determine the 
particle size distribution are dynamic light scattering techniques, microscopic techniques etc. 
The laser diffraction technique is used to detect microparticles or possible aggregates of drug 
nanoparticles. 
 
Particle Charge / Zeta Potential  
 
Zeta potential is the charge at particles mobile surface and is used to determine the 
degree of flocculation or deflocculation in nanosystems. Zeta potential measurement is carried 
out to optimize formulation parameters and to make predictions regarding the storage stability 
of the colloidal dispersion. Its value may be positive or negative depending on nature of, drug, 
polymer adsorbed ions. A sufficiently high zeta potential (positive or negative) indicates that 
the system shall be deflocculated as for aggregation particles have to overcome the 
electrostatic energy barrier.  
 
Crystalline Status  
 
Differential scanning calorimetric, X ray diffraction and other analytical methods are 
used to assess any possible changes brought about in the physical form, amorphous or 
crystalline structure and other polymorphic changes in the drug during formulation. Presence of 
different polymorphs can also be assessed by X ray diffractometer. 
 
Toxicity Evaluation  
 
Nanoparticles are also associated with some acute and long term toxicities determined 
in various animal models. Some important acute toxicities associated with nanosystem are 
enhanced endocytosis resulting in inflammation and granuloma formation; oxidative stress 
causing cell death due to free radical generation and altered and/or modified protein/gene 
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structure resulting in immune responses. The long-term toxicities associated with nanosystems 
are bioaccumulation, poor biodistribution and ultimate fate of nanosystem in body [30]. 
 
Macroscopic aspect of freeze-dried product 
 
A freeze-dried product is observed to assess of the final volume and the appearance of 
the cake. One of the desired characteristics of a freeze-dried pharmaceutical form is to yield an 
intact cake occupying the same volume as the original mass. An attentive microscopic 
examination of the freeze dried cake must be carried out in order to detect any shrinkage or 




To rehydrate the freeze-dried nanoparticles one must add the same volume of water 
lost after lyophilization. The time of reconstitution may be recorded. In general, freeze-dried 
product rehydrates immediately after the addition of water, but in some cases, a long 
reconstitution time could be obtained as in the case of collapsed formulations. Many methods 
could be used to achieve the re-suspension of freeze dried nanoparticles after the addition of 
water, as manual shaking, vortexing or sonication to ensure full re-suspension. Measurement of 
nanoparticles size and zeta potential after freeze-drying after reconstitution, nanoparticles size 
must be measured by photon correlation spectroscopy or another technique. The conservation 
of a nanoparticle diameter size after freeze-drying is considered as a good indication of a 
successful freeze-drying cycle. In general, the ratio of nanoparticles size after and before freeze-
drying may be calculated. A value near from one indicates the conservation of nanoparticles 
size, whereas an important value of this ratio indicates the aggregation of nanoparticles. 
Furthermore, the index of polydispersity may be recorded after lyophilization. This index gives 
also an idea about the distribution of nanoparticles size and its value must be compared to the 
value before freezedrying, to evaluate the conservation of nanoparticles distribution. The 
measurement of zeta potential is a good method to evaluate the state of nanoparticles surface 
and to detect any eventual modification after freeze-drying. Furthermore, it can be used to 
study the interaction between the cryoprotectant molecules and the nanoparticles surface. It 
has been found that the addition of 10% of sucrose to itraconazole loaded poly(ε-caprolactone) 
nanospheres suspension before freeze-drying decreased the negative surface charge from 
−40.9 mV to −20.4 mV. The authors explain this by the fact that nanosphere surface being 
masked as a result of hydrogen bonding between OH groups of the cryoprotectant agent and 
the surface of the nanospheres. After freeze-drying, the decrease in the negative surface charge 
is accentuated, showing a rearrangement of the surfactants (poloxamer) at the surface of the 
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Table 1: Nanoparticles available in National and International Market 
 
Sr No. Brand Name Active Ingredients Indications Name of Company 
1 Adagen Adinosine deaminase Adenosine deaminase 
(ADA) enzyme deficiency 
Ezon Pharmaceuticals 
inc., Bridgewater, NJ, 
USA 
2 Onscaspar L-asparginase Acute Lymphoblastic 
leukaemia 
Enzon Pharmaceuticals 
inc., NJ, USA 








San Carlos, CA, USA; OSI 
Pharmaceuticals, 
Melville, NY, USA 
5 Pegasys Pegylated interferon 
alfa-2a 
Hepatitis C Nektar Therapeutics, CA, 
USA 
6 Neulasta Pegfilgrastim Neutopenia Nektar Therapeutics, CA, 
USA; Amgen inc, 
Thousand Oaks, CA, USA 
7 PEG-INTRON Peginterferon alfa-2b Hepatitis C Nektar therapeutics, CA, 
USA 
8 Somavert Pegvisomant Acromegaly Nektar Therapeutics, CA, 
USA 
9 Protein (Albumin) 
Nanoparticles 
Abraxane Paclitaxel Abraxix bioscience, 
Losangles, CA, USA, 
Astra Zeneca, Landon, 
UK 
10 Rapamune Sirolimus Immunosupressant Wyeth Pharmaceuticals 
11 Megace ES Megestrol acetate Treatment of anorexia, 
cachexia 
Par Pharmaceuticals 
12 Emend Aprepitant Antiemetic Merck 
13 Tricor Fenofibrate Antihyperlipidemic agent Abbott Laboratories 
14 Triglide Fenofibrate Antihyperlipidemic agent Skye Pharma  
15 Panzem NCD 2-Methoxy estradiol Estrozen metabolite Entre Med Inc. 
16 Sandummine 
Neoral 
Cyclosporine Immunosupressant Novartis 
17 Gengraf Cyclosporine Immunosupressant Abbott Laboratories 
18 Norvir Ritonavir Anti-retrovial Abbott Laboratories 
19 Fortovase Saquinavir Anti-retrovial Hoffman-La Roche 
20 Feridex/Endorm Iron Nanoparticles Liver Tumor Imaging Advance 
Magnetics(USA) 
 
Microscopic observation of freeze-dried product 
 
The microscopic visualization of freeze-dried product is a direct way on the one hand to 
observe the microstructure of the freeze-dried matrix, on the other hand to prove the 
conservation of nanoparticles integrity and to observe whether any modification has occurred 
on their morphology. Many high resolution microscopic techniques are being used to observe 
the nanoparticle formulation after freeze-drying: transmission electron microscopy (TEM), 
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cryogenic transmittance electron microscopy (cryo-TEM), atomic force microscopy (AFM), 
scanning electronic microscopy (SEM), environmental scanning electronic microscopy (ESEM). 
TEM was also used to observe freeze-dried itraconazole- loaded nanospheres and poly (ε-
caprolactone) nanocapsules after reconstitution. It is clear from TEM image that nanocapsules 
were well conserved after freeze-drying using PVP as cryoprotectant. The polymeric membrane 
was intact around the oily cavity of nanocapsules. An amorphous matrix of PVP could be 
observed at the outer surface of nanocapsules. Furthermore, freeze-dried core shell 
nanoparticles have been imaged by cryogenic transmittance electron microscopy to verify the 
formation of core/shell nanoparticles. Freeze-dried cationically modified silica nanoparticles 
using 5% of trehalose as cryoprotectant could be observed by AFM. It could be found from AFM 
images, that trehalose formed a matrix into which the nanoparticles were inter dispersed. 
ESEM imaging showed spherical mono disperse nanocapsules being well conserved after 
freeze-drying. ESEM offers the possibility to control the dehydration of sample by gradual 
reduction of pressure and temperature in the sample chamber. Such samples can be observed 
in a hydrated state without a complete drying which prevents the observation of individual 
nanocapsules. Furthermore, this technique has the ability to image wet systems without prior 
sample preparation. Finally, ESEM is the best technique for observing of lyophilized 
nanocapsules in a hydrated state. The advantages of ESEM over SEM for observing colloidal 
particles with minimal perturbation are the possibility to observe hydrated samples in their 
native state, without need of conductive coating of the samples and no need of the preparation 
of the samples. ESEM is the most adequate technique to observe nanoparticles in a hydrated 
state [75]. 
 
Thermal analysis by differential scanning calorimetry (DSC) 
 
During storage, freeze-dried nanoparticles included within a vitrified matrix of 
lyoprotectant must be stored at a temperature below the temperature of glass transition (Tg) 
of the dried formulation to prevent any shrinkage of the freeze-dried cake or any 
destabilization of included nanoparticles as a result of lyoprotectant crystallization. The 
temperature of glass transition may be determined by differential scanning calorimetry. 
Furthermore, this technique is very useful to study the interaction between the lyoprotectant 
and the nanoparticles. For example, in the case of solid lipid nanocapsules freeze-dried with 
trehalose, DSC study points out a complexation between lecithin (forming the shell of 
nanocapsules) and trehalose, reinforcing the stabilizing properties of lecithin [7]. 
 
Drug content determination 
 
The drug content in nanoparticles must be determined by an adequate analytical 
method measuring both free drug concentration as well as entrapped drug concentration using 
High and its value must be compared to that before freeze-drying to detect any leakage of drug 
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Powder surface analysis 
 
The elemental composition of the powder surface of freeze-dried nanocapsules can be 
analyzed by electron spectroscopy for chemical analysis (ESCA). This technique is based on the 
emission of electrons, in response to irradiation by photons of sufficient energy. These 
electrons are emitted at energies characteristics of the atoms from which they are emitted. 
ESCA has been repoted to be used for studying the surface modification of nanoparticles, and 
the adsorption of proteins at the air/liquid interface during spray-drying and adsorption on the 
ice crystals surface in the freeze-dried product. Such studies have a significant importance 
especially in the case of freeze-drying of immuno-nanoparticles which have antibodies 
adsorbed at their surface. The adsorption of protein at the interface ice/liquid during the 
freezing can disrpt their native fold and results in surface induced denaturation of proteins. 
Surfactants may drop surface tension of protein solutions and reduce the driving force of 
protein adsorption at the interface ice/liquid. Low concentrations of nonionic surfactants such 
as tween 80 are often sufficient to prevent surface adsorption. 
 
Study of water sorption and determination of residual moisture 
 
The thermal and the structure properties of freeze dried nanoparticles are influenced by 
residual moisture present in the product. Residual moisture is determined by the water 
desorption process during secondary drying. Sorption isotherm of water study is realized in 
order to determine on the one hand the degree of hygroscopicity of the product and to assess 
the ease in secondary drying. In general, the easier the water adsorption, the easier water 
desorption. The content of residual moisture in freeze-dried nanoparticles can be determined 
by Karl Fischer titration or by other methods as the gravimetric method or the thermal 
gravimetric analysis (TGA). 
CONCLUSION 
 
Nanoparticle technology is a fast growing field of activity that will allow development of 
materials with brand new properties. The major goals in designing nanoparticles as a delivery 
system are to control particle size, surface properties, enhance solubility and release of 
pharmacologically active agents in order to achieve the site-specific action of the drug at the 
therapeutically optimal rate and dose regimen. A successful NPs system may be one which has 
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